Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 202

Results For "NDA"

3698 News Found

NHA introduces new system to measure hospitals performance empaneled under AB PM-JAY Scheme
Policy | January 10, 2023

NHA introduces new system to measure hospitals performance empaneled under AB PM-JAY Scheme

The objective of this system is to shift the focus of measuring performance of hospitals from volume of services provided to value of healthcare services


Vidita Vaidya awarded Infosys Prize 2022 in Life Sciences
News | January 10, 2023

Vidita Vaidya awarded Infosys Prize 2022 in Life Sciences

In a time when conversations around mental health have become ever more urgent Vaidya’s work is extremely contextual


Zydus receives final approval from the USFDA for Febuxostat Tablets
Drug Approval | January 10, 2023

Zydus receives final approval from the USFDA for Febuxostat Tablets

Febuxostat tablets had annual sales of USD 32 million in the United States according to IQVIA data (IQVIA MAT Sept. 2022).


Suburban Diagnostics unveils Reference Laboratory in Mumbai
Diagnostic Center | January 09, 2023

Suburban Diagnostics unveils Reference Laboratory in Mumbai

The lab is also the first private lab in West India to have built its Mycobacteriology, Mycology, and Molecular Biology departments within a separate Bio Safety Level - 3 (BSL3) bio-containment lab


Protein found in Zebrafish can regenerate aged discs in human vertebrae
News | January 09, 2023

Protein found in Zebrafish can regenerate aged discs in human vertebrae

A study by Agharkar Research Institute (ARI), Pune, has discovered that a protein secreted from intervertebral disc cells induces disc regeneration in aged degenerated discs


Lupin receives approval from USFDA for Fesoterodine Fumarate Extended-Release Tablets
Drug Approval | January 07, 2023

Lupin receives approval from USFDA for Fesoterodine Fumarate Extended-Release Tablets

Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, (RLD Toviaz®) had estimated annual sales of USD 177 million in the U.S. (IQVIA MAT September 2022).


Dabur India expects low to mid-single digit revenue growth for Q3 FY23
News | January 07, 2023

Dabur India expects low to mid-single digit revenue growth for Q3 FY23

International Business is expected to post double-digit revenue growth during the quarter in constant currency.


Alembic receives USFDA final approval for Fesoterodine Fumarate Extended-Release Tablets
Drug Approval | January 07, 2023

Alembic receives USFDA final approval for Fesoterodine Fumarate Extended-Release Tablets

Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, have an estimated market size of US$ 177 million for twelve months ending Sep 2022


Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma
News | January 06, 2023

Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma

The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”